Samsung medical center

Seoul, Gangnam-gu 6351

4 studies enrolling now · 16 studies all time

What they study most

Acral Melanoma, Acute Myeloid Leukemia, Advanced Solid Tumor, Anemia, Basal Cell Carcinoma, Bladder Cancer, Cancer With A High Tumor Mutational Burden, Cardiovascular Diseases, Cervical Cancer, Cervical Cancers, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Extrahepatic

Studies at this site

• A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib — Recruiting now
• Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC — Recruiting now
• Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer — Recruiting now
• A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors — Recruiting now
• A Beta-only IL-2 ImmunoTherapY Study — Recruiting now
• A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients — Completed
• A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension — Enrolling by invitation
• Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients — Stopped early
• A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors — Stopped early
• To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF — Completed
• Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers — Stopped early
• Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP — Completed
• Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC) — Completed
• MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing — Stopped early
• Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma — Stopped early
• Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma — Completed